Wednesday, December 11, 2013

List of Cravings

For The FULL List of Cravings Click THIS Link: http://bit.ly/1gXUaXz

What are your food cravings really telling you? Usually when you crave something, that is your brain signalling that it is lacking a certain nutrient, and so it will automatically gravitate to the things that are easy, un-healthy and leave us wanting more (since the foods we often gravitate to will momentarily satisfy us, however, our brains will keep on firing, and telling us to eat more – since we didn’t give it the proper nutrients – which leads us into a rabbit hole of over-eating)...Read MORE By Clicking The Link ABOVE!

CONCORD, N.H. (AP) — David Kwiatkowski’s six-month stint at the Baltimore Veterans Affairs medical center was about to end in 2008 when a doctor proposed extending the traveling technician’s contract. Don’t do it, one nurse warned.
‘‘If you keep him, we’re going to management, the police, and outside the VA, because you would be putting our licenses in jeopardy,’’ the nurse, Ron Warnick, said amid suspicions that Kwiatkowski was tampering with medications, according to recently released court documents.
Kwiatkowski’s contract wasn’t extended, but he went on to work in nine more hospitals in five states, stealing drugs and infecting patients with hepatitis C through tainted syringes along the way. The criminal case against him ended last week when he was sentenced to 39 years in prison for 16 federal drug convictions in New Hampshire. Now the push is for hospitals, state lawmakers and federal officials to fix the problems his prosecution revealed.
Kwiatkowski’s ‘‘trail of infection’’ helped unmask a problem that was a growing concern for the Centers for Disease Control and Prevention and across the public health system, said Joseph Perz, who specializes in injection safety and infection control at the CDC.
‘‘If there is a silver lining, it is that we’re seeing some movement toward broader prevention, and that’s a very good thing,’’ he said.
Medical technicians aren’t as closely regulated as doctors or nurses, and there is no nationwide database of misconduct or disciplinary actions against them, as there is for physicians. While some states require certain technicians to be licensed, four of the states where Kwiatkowski worked don’t license any of them.
Hospitals and staffing agencies are supposed to share responsibility for verifying that workers have licensing and good reputations, but Kwiatkowski was able to move from job to job and state to state despite having been fired numerous times over allegations of drug use and theft. In one case, police were called but declined to bring charges; in another, he was fired but not reported to police.
In all, patients were infected in New Hampshire, Maryland, Kansas and one Pennsylvania. Kwiatkowski also worked in Michigan, New York, Arizona and Georgia.
Since his arrest in July 2012, more than 12,000 people have been asked to get tested for hepatitis C, a blood-borne virus that can cause liver disease and chronic health problems, and 46 people been diagnosed with the same strain of the virus he carries.
‘‘This defendant exploited critical gaps in reporting requirements to law enforcement, licensing authorities and the staffing agencies that place them throughout the country,’’ said U.S. Attorney John Kacavas, who prosecuted Kwiatkowski. Saying Kwiatkowski ‘‘cast a harsh light on the dirty little secret of drug diversion’’ in medical facilities, Kacavas has directed his office to work with other agencies to recommend tighter regulation in the hiring and management of health care workers.
In Maryland, where seven patients contracted hepatitis C from Kwiatkowski, lawmakers passed a bill requiring staffing agencies that find jobs for health care workers to obtain licenses. The state public health department also urged the state Board of Physicians to review its procedures for licensing health care professionals, noting that Kwiatkowski falsely obtained a radiographer certification and a Maryland license because no one verified what he had put down on his applications.
New Hampshire is one of several states that doesn’t license workers like Kwiatkowski, but that would change under pending legislation. Lawmakers are considering a bill that would create a licensing system for medical technicians and a registry that other states could search. Another bill would require hospitals to test employees for drugs if there was a reasonable suspicion of drug use.
New Hampshire officials also have been working with an advocacy group founded by a cancer patient who was infected with hepatitis C at a Nebraska clinic in 2002 when a saline bag that had been used on an infected patient was reused. Steve Langan, director of Hepatitis Outbreaks National Organization for Reform in Nebraska, is meeting with federal Department of Health and Human Services officials next month, when he plans to push the agency to make preventing drug diversion a bigger priority.
‘‘This is an immense, multifaceted problem, and until we truly engineer safety into the health care system, there’s going to be a risk,’’ he said.Page 2 of 2 --
Besides taking steps to better secure narcotic drugs, Perz said hospitals need to ask more questions when a worker gets caught. In the Kwiatkowski case, the investigation into a hepatitis C outbreak led to the discovery he was stealing drugs, but ‘‘we need to come at it the other way, too,’’ Perz said. That means when a worker steals injectable drugs, hospitals need to test that worker for hepatitis C and other diseases and determine whether patients were put at risk.
That didn’t happen in Kwiatkowski’s case until he got to New Hampshire, but Perz said he believes there is momentum for change.
‘‘We’re at the point where there’s growing awareness of what’s been largely a hidden problem,’’ he said.

Gilead Hep C Drug Launch Threatened by Price Concerns

Gilead Hep C Drug Launch Threatened by Price Concerns

Stock quotes in this article: GILDABBVENTAESRX 
Updated with analyst defense of Gilead Sciences

The top medical officer for pharmacy benefits manager Express Scripts  (ESRX_) expressed concerns about high pricing for the new crop of hepatitis C pills, most notably Gilead Sciences' (GILD_) Sovaldi, according to a Bloomberg story Tuesday.

Solvadi may be pitted against other hepatitis C therapies, Express Scripts' chief medical officer said, and "tough formulary decisions" will be made. 

Shares of Gilead are down 4.5% to $71.84 after the Bloomberg story hit the wires. Shares of Abbvie, on the other hand, are up 4.5% to $53.51. 

The FDA approved Gilead's Sovaldi on Friday and the drug is priced at $1,000 per pill, or $84,000 for a 12-week course of therapy.

Abbvie's Hep C regimen is expected to be approved next year. If the company prices the drug cocktail right, it may gain extra market share and revenue, based on the Express Scripts comments today.

Shares of Enanta Pharma (ENTA_), which contributes a drug to the Abbvie regimen and will receive royalties on sales, are up 18% to $35.10.

Here are some tweets from Bloomberg reporter Drew Armstrong on the interview with Express Scripts' chief medical officer:

EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus

The European Association for the Study of the Liver (EASL) today publishes their revised Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection (HCV) (1). The EASL guidelines, which supersede the previous version published in 2011, are designed to help physicians and other healthcare providers optimise their management of patients with acute and chronic HCV.
It is estimated that approximately 160 million individuals, i.e. 2.35% of the world's population, are chronically infected with HCV. In the European Union alone, between 7.3 and 8.8 million people are infected with HCV, double the previous estimate made in 1997. The prevalence varies across the region with higher rates seen in the south and the east, making HCV a critical area of attention for hepatologists as one fifth of HCV-infected patients are at risk of developing cirrhosis or liver cancer (2).
HCV CPG co-chair reviewer and consultant hepatologist at Queen Elizabeth Hospital, Birmingham, Professor David Mutimer said: "As our understanding of HCV increases and therapies evolve, more complex treatment strategies are necessary to achieve the primary goal of curing the infection.
"Since EASL published the last HCV CPG in 2011, two protease inhibitors have been approved for use in patients infected with HCV genotype 1. These first-generation direct-acting antivirals are the first of many direct acting antiviral drugs which will revolutionise treatment for HCV patients, including those who failed to respond to previous therapies. The new guidelines provide essential information on the recommended use of these newly licensed drugs to help prescribers deliver optimal care for their HCV patients."
EASL publishes updated clinical practice guidelines to optimise the management of hepatitis C virus infection.
(Photo Credit: EASL)
Based on a systematic review of existing literature, the CPGs provide best practice recommendations on a number of key areas:
  • Current standard of care and developing therapies
  • Diagnosis of acute and chronic hepatitis C
  • Goals and endpoints of HCV therapy
  • Indications for treatment and who should be treated
  • Treatment strategies for different viral genotypes
  • Treatment monitoring including virological response-guided triple, and dual therapy
  • Monitoring treatment safety
  • Treatment of special groups including HIV co-infection, hepatitis B co-infection and patients with other co-morbidities such as severe liver disease
The guidelines also contain significant discussion about people who inject drugs (PWID*) providing an overview of the published literature relating to the treatment of these patients, and covering issues such as:
  • Re-infection following successful HCV treatment in patients at high risk (such as PWID)
  • The burden of chronic HCV and advanced liver disease among ageing cohorts of PWID
Professor Mutimer added: "With HCV spread among PWID now accounting for the vast majority of incident cases in developed countries, and with modelling studies suggesting that treatment for PWID could reduce transmission, it is critical that physicians review and adopt these guidelines when managing this important group of patients."
Commenting on the CPGs, EASL Secretary General Professor Markus Peck-Radosavljevic said "EASL is dedicated to promoting hepatology research and education to improve the worldwide treatment of liver disease. As treatment for hepatitis C continues to progress rapidly with the development and approval of new therapies, it's vital to ensure that our series of Clinical Practice Guidelines reflect best practice to drive better clinical outcomes.
"As there have been several key clinical and scientific advances over the past two years, these guidelines build upon the recommendations reported by the EASL HCV panel of experts in 2011. EASL encourage clinicians to refer to these new HCV guidelines for the most up-to-date, evidence based methods to offer patients first class treatment."

New, expensive pill may aid Hepatitis C treatment

New, expensive pill may aid Hepatitis C treatment

Print
Font Size:
Default font 
Larger font size
Posted: Sunday, December 8, 2013 6:00 pm
The Food and Drug Administration on Friday approved a pill that is expected to make the treatment of hepatitis C less onerous, shorter in duration and more effective.
The drug, Sovaldi, from Gilead Sciences, will allow some patients infected with the liver-destroying virus to be treated only with pills, doing away with weekly injections of a drug that can have debilitating side effects.
“Today’s approval represents a significant shift in the treatment paradigm for some patients with chronic hepatitis C,” said Dr. Edward Cox, director of the office of antimicrobial products at the FDA.
But the greater convenience and effectiveness comes at a price. Gilead said the wholesale cost of Sovaldi, which is known generically as sofosbuvir, would be $28,000 for four weeks, or $1,000 per daily pill. That translates to $84,000 for the 12 weeks of treatment recommended for most patients, and $168,000 for the 24 weeks needed for a hard-to-treat strain of the virus.
The Initiative for Medicines, Access and Knowledge, a legal group based in New York, recently filed a motion to try block patenting of the drug in India. If it succeeds, generic manufacturers in India would be able to manufacture cheap copies of the drug for distribution there and in some other developing countries.
Gilead said the price was fair given the drug’s higher cure rate and that the total cost for the 12-week regimen was “consistent with, and in some cases lower than” the cost of some other regimens for hepatitis C.
Some 3 million to 4 million Americans, many of them in middle age, are believed to have a chronic hepatitis C infection, though many do not know it. The virus slowly damages the liver, leading to cirrhosis and in some cases to liver cancer. But it often takes decades before any damage is noticeable, and many people never experience a problem.
Globally, at least 150 million people have hepatitis C.
Sales are expected to be strong from the start, because many patients, on the advice of their doctors, have been putting off starting treatment until Sovaldi became available.

FDA Approves New Treatment For Chronic Hepatitis C

FDA Approves New Treatment For Chronic Hepatitis C

December 8, 2013

redOrbit Staff & Wire Reports – Your Universe Online
Sovaldi (sofosbuvir), a new drug that can treat hepatitis C infections, has been approved for sale by the US Food and Drug Administration (FDA), agency officials confirmed on Friday.
According to Kim Painter of USA Today, the medication is manufactured by Gilead Sciences and “can be paired with other drugs to make treatment of the liver-damaging disease faster, easier and more effective.”
Dr. Edward Cox, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research, called the approval “a significant shift in the treatment paradigm for some patients with chronic hepatitis C.” The drug is the second to get the go-ahead from the FDA to treat the condition in less than a month, following the November 22 approval of Olysio (simeprevir).
The drug, which will be available in pill form, will allow some of the over three million Americans to be treated without co-administration of interferon, which can have flu-like side effects, the Wall Street Journal added. In clinical trials, Sovaldi was found to cure hepatitis C in 90 percent of patients when used in tandem with one or more other drugs, which varied based on the specific type of the disease those individuals had contracted.
However, “the greater convenience and effectiveness comes at a price,” New York Times reporter Andrew Pollack wrote. “Gilead said the wholesale cost of Sovaldi… would be $28,000 for four weeks – or $1,000 per daily pill. That translates to $84,000 for the 12 weeks of treatment recommended for most patients, and $168,000 for the 24 weeks needed for a hard-to-treat strain of the virus.”
Michael Weinstein, president of the AIDS Healthcare Foundation, told Pollack the cost was “completely unjustified,” but Gilead countered that the price was fair in light of the medication’s high cure rate. Furthermore, the pharmaceutical company said the overall cost for the three-month regimen was “consistent with, and in some cases lower than” the cost of other hepatitis C treatments, and that financial assistance would be available to some patients.
Sovaldi is described by the FDA as a nucleotide analog inhibitor, which blocks a protein required for the hepatitis C virus to replicate. It is to be used as one part of a combination treatment for chronic infection, and is to be taken in conjunction with peginterferon-alfa and/or ribavirin. The six clinical trials used to evaluate it involved nearly 2,000 patients who had either not received treatment or had not responded to previous treatment attempts.
Dr. John Ward, director of the Division of Viral Hepatitis at the US Centers for Disease Control and Prevention (CDC), told CNN that this is a “landmark advance in the treatment of hepatitis C, opening up new opportunities to stop the spread of this virus and the ravages of this disease.” However, he also emphasized these treatments are only effective if they can get “more people screened and into care. Right now, most Americans with hepatitis C don’t access treatment because they have no idea they’re infected.”

Source: redOrbit Staff & Wire Reports – Your Universe Online

Read more at http://www.redorbit.com/news/health/1113022674/sovaldi-sofosbuvir-chronic-hepatitis-c-infection-treatment-medicine-fda-approval-120813/#Wx6gt9c2eZWUwYj1.99

Hepatitis C: All that you need to know about the silent killer


Hepatitis C: All that you need to know about the silent killer

Zee Media Bureau/Salome Phelamei
Hepatitis is an infectious liver disease caused by the hepatitis C virus (HCV). Its severity ranges from a mild illness lasting a few weeks to a serious lifelong sickness. According to the World Health Organisation (WHO), about 150 million people are chronically infected with hepatitis C virus, and more than 350,000 people die yearly from hepatitis C-related liver diseases.
How Hepatitis C spreads?
Of the several hepatitis viruses, hepatitis C is believed to be among the most serious. Hepatitis C is transmitted through contact with infected blood. It can also be contracted through:
Sharing drugs and needles
Having unprotected sex with an infected person
From mother to baby during child birth
What are the signs and symptoms of Hepatitis C?
Generally, hepatitis C shows no signs and symptoms during initial stages. If signs and symptoms do happen, they may include:
Fever
Fatigue
Nausea
Vomiting
Abdominal pain
Loss of appetite
Joint pain and jaundice
How can it be treated?
While hepatitis C can be treated using antiviral medicines, treatment is not always essential. Before undertaking any treatment, careful screening is vital for the patients to find out the most appropriate approach.
Interferon and ribavirin are used to treat Hepatitis C. Owing to scientific advancement, new antiviral drugs for hepatitis C have been developed, which may be more effective and better tolerated than existing therapies. As per the WHO, two new therapeutic agents — telaprevir and boceprevir — have recently been licensed in some countries.
Can Hepatitis C be prevented?
Currently, there is no vaccine for hepatitis C. But, the risk of infection can be reduced by following a few tips:
Avoid sharing personal care items like razors
Be cautious if you are getting a tattoo or body piercing, check if the apparatus being used is clean
Avoid having sex with hepatitis C-infected person or use a latex condom every time you have sex
Avoid sharing needles
If you are infected with hepatitis C virus, avoid spreading it by not donating blood or tissue.
 Source salome phelamei